ATRA
Price
$7.95
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
47.54M
CASI
Price
$1.20
Change
-$0.10 (-7.69%)
Updated
Jun 27 closing price
Capitalization
18.59M
Interact to see
Advertisement

ATRA vs CASI

Header iconATRA vs CASI Comparison
Open Charts ATRA vs CASIBanner chart's image
Atara Biotherapeutics
Price$7.95
Change-$0.00 (-0.00%)
Volume$43
Capitalization47.54M
CASI Pharmaceuticals
Price$1.20
Change-$0.10 (-7.69%)
Volume$30.57K
Capitalization18.59M
ATRA vs CASI Comparison Chart in %
Loading...
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATRA vs. CASI commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a Buy and CASI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ATRA: $7.95 vs. CASI: $1.20)
Brand notoriety: ATRA and CASI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 0% vs. CASI: 23%
Market capitalization -- ATRA: $47.45M vs. CASI: $18.59M
ATRA [@Biotechnology] is valued at $47.45M. CASI’s [@Biotechnology] market capitalization is $18.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileCASI’s FA Score has 0 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • CASI’s FA Score: 0 green, 5 red.
According to our system of comparison, ATRA is a better buy in the long-term than CASI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 2 TA indicator(s) are bullish while CASI’s TA Score has 4 bullish TA indicator(s).

  • ATRA’s TA Score: 2 bullish, 5 bearish.
  • CASI’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, CASI is a better buy in the short-term than ATRA.

Price Growth

ATRA (@Biotechnology) experienced а +0.13% price change this week, while CASI (@Biotechnology) price change was -9.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATRA($47.5M) has a higher market cap than CASI($18.6M). ATRA YTD gains are higher at: -40.270 vs. CASI (-57.597). ATRA has higher annual earnings (EBITDA): -5.74M vs. CASI (-38.42M). ATRA has more cash in the bank: 13.8M vs. CASI (12.7M). CASI has less debt than ATRA: CASI (18.5M) vs ATRA (40.6M). ATRA has higher revenues than CASI: ATRA (200M) vs CASI (31.4M).
ATRACASIATRA / CASI
Capitalization47.5M18.6M255%
EBITDA-5.74M-38.42M15%
Gain YTD-40.270-57.59770%
P/E RatioN/AN/A-
Revenue200M31.4M637%
Total Cash13.8M12.7M109%
Total Debt40.6M18.5M219%
FUNDAMENTALS RATINGS
ATRA vs CASI: Fundamental Ratings
ATRA
CASI
OUTLOOK RATING
1..100
8095
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5796
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CASI's Valuation (73) in the Biotechnology industry is in the same range as ATRA (74). This means that CASI’s stock grew similarly to ATRA’s over the last 12 months.

CASI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATRA (100). This means that CASI’s stock grew similarly to ATRA’s over the last 12 months.

CASI's SMR Rating (100) in the Biotechnology industry is in the same range as ATRA (100). This means that CASI’s stock grew similarly to ATRA’s over the last 12 months.

ATRA's Price Growth Rating (57) in the Biotechnology industry is somewhat better than the same rating for CASI (96). This means that ATRA’s stock grew somewhat faster than CASI’s over the last 12 months.

ATRA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CASI (100). This means that ATRA’s stock grew similarly to CASI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRACASI
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
77%
Aroon
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CHEK0.770.01
+0.78%
Check-Cap Ltd
XMTR33.620.22
+0.66%
Xometry
NVST19.65N/A
N/A
Envista Holdings Corp
CCEP91.10-0.17
-0.19%
Coca-Cola Europacific Partners plc
GEVO1.25N/A
-0.40%
Gevo

ATRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATRA has been loosely correlated with AMLX. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRA jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATRA
1D Price
Change %
ATRA100%
N/A
AMLX - ATRA
65%
Loosely correlated
N/A
GRI - ATRA
40%
Loosely correlated
-0.78%
SLRX - ATRA
39%
Loosely correlated
-0.01%
FULC - ATRA
35%
Loosely correlated
-3.79%
FOLD - ATRA
34%
Loosely correlated
N/A
More

CASI and

Correlation & Price change

A.I.dvisor tells us that CASI and ATRA have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASI and ATRA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CASI
1D Price
Change %
CASI100%
-7.69%
ATRA - CASI
33%
Poorly correlated
N/A
RIGL - CASI
30%
Poorly correlated
+3.73%
ADCT - CASI
29%
Poorly correlated
+0.37%
VICP - CASI
29%
Poorly correlated
N/A
SRPT - CASI
28%
Poorly correlated
-0.70%
More